Ross procedure provides survival benefit over mechanical valve in adults: a propensity-matched nationwide analysis

• Published in: European journal of cardio-thoracic surgery Vol. 61; no. 6; pp. 1357 - 1365
• Main Authors: Gofus, Jan, Fila, Petr, Drabkova, Svetlana, Zacek, Pavel, Ondrasek, Jiri, Nemec, Petr, Sterba, Jan, Tuna, Martin, Jarkovsky, Jiri, Vojacek, Jan
• Format: Journal Article
• Language: English
• Published: Germany Oxford University Press 27.05.2022
• Subjects: Propensity score matching; Ross procedure; Aortic valve replacement; Midterm survival; Nationwide analysis; Mechanical prosthesis
• ISSN: 1010-7940; 1873-734X
• DOI: 10.1093/ejcts/ezac013

Abstract OBJECTIVES The choice of optimal surgical treatment for young and middle-aged adults with aortic valve disease remains a challenge. Mechanical aortic valve replacement (mAVR) is generally preferred despite promising recent outcomes of the Ross procedure. Our goal was to compare the strategies at a nationwide level. METHODS This study was a retrospective analysis of prospectively recorded data from the National Registry of Cardiac Surgery of the Czech Republic. Using propensity score matching, we compared the outcomes of patients undergoing the Ross procedure in 2 dedicated centres with all mAVRs performed in country between 2009 and 2020. RESULTS Throughout the study period, 296 adults underwent the Ross procedure and 5120 had an mAVR. We found and compared 291 matched pairs. There were no in-hospital deaths, and the risk of perioperative complications was similar in both groups. Over the average follow-up period of 4.1 vs 6.1 years, the Ross group had a lower all-cause mortality (0.7 vs 6.5%; P = 0.015). This result remained significant even when accounting for cardiac- and valve-related deaths only (P = 0.048). Unlike the Ross group, the mAVR group had a significantly lower relative survival compared with the age- and sex-matched general population. There was no difference in the risk of reoperation (4.5 vs 5.5%; P = 0.66). CONCLUSIONS The Ross procedure offers a significant midterm survival benefit over mAVR. The procedures have a comparable risk of perioperative complications. Patients after mAVR have reduced survival. Thus, the Ross procedure should be the preferred treatment option for young and middle-aged adults with aortic valve disease in dedicated centres. The Ross procedure was first described by Donald Ross in 1967 [1].